CY1116592T1 - COGNITIVE THERAPY CONTAINING α5β1 COMPONENTS - Google Patents
COGNITIVE THERAPY CONTAINING α5β1 COMPONENTSInfo
- Publication number
- CY1116592T1 CY1116592T1 CY20151100696T CY151100696T CY1116592T1 CY 1116592 T1 CY1116592 T1 CY 1116592T1 CY 20151100696 T CY20151100696 T CY 20151100696T CY 151100696 T CY151100696 T CY 151100696T CY 1116592 T1 CY1116592 T1 CY 1116592T1
- Authority
- CY
- Cyprus
- Prior art keywords
- components
- relates
- present
- therapy containing
- cognitive therapy
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με την χρήση ανταγωνιστών VEGF και ανταγωνιστών α5β1 για θεραπευτική αγωγή καρκίνου και αναστολή αγγειογένεσης και/ή αγγειακής διαπερατότητας, συμπεριλαμβανομένης αναστολής ανώμαλης αγγειογένεσης σε ασθένειες. Η παρούσα εφεύρεση σχετίζεται επίσης με την χρήση αγωνιστών VEGF και αγωνιστών α5β1 σε προαγωγή αγγειογένεσης και αγγειακής διαπερατότητας. Η παρούσα εφεύρεση σχετίζεται επίσης με νέα αντισώματα αντι-α5β1, συνθέσεις και κιτ που τα περιλαμβάνουν και με μεθόδους παρασκευής και χρήσης τους.The present invention relates to the use of VEGF antagonists and α5β1 antagonists for the treatment of cancer and inhibition of angiogenesis and / or vascular permeability, including inhibition of abnormal angiogenesis in diseases. The present invention also relates to the use of VEGF agonists and α5β1 agonists in promoting angiogenesis and vascular permeability. The present invention also relates to novel anti-α5β1 antibodies, compositions and kits comprising them and to methods for their preparation and use.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78470406A | 2006-03-21 | 2006-03-21 | |
US78533006A | 2006-03-22 | 2006-03-22 | |
US87174306A | 2006-12-22 | 2006-12-22 | |
EP07868188.9A EP1989231B1 (en) | 2006-03-21 | 2007-03-21 | Combinatorial therapy involving alpha5beta1 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116592T1 true CY1116592T1 (en) | 2017-03-15 |
Family
ID=58459758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100696T CY1116592T1 (en) | 2006-03-21 | 2015-08-10 | COGNITIVE THERAPY CONTAINING α5β1 COMPONENTS |
Country Status (1)
Country | Link |
---|---|
CY (1) | CY1116592T1 (en) |
-
2015
- 2015-08-10 CY CY20151100696T patent/CY1116592T1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117319T1 (en) | TRICYCLIC AMIN PRODUCTS AS PROTEIN TYSINE MUSCLE INSPECTORS | |
CY1120866T1 (en) | DNA-PK INHIBITORS | |
CY1124928T1 (en) | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | |
CY1116886T1 (en) | C-MET ACCESSORIES | |
CY1120913T1 (en) | MONOCLONIC ANTIBODIES AGAINST PROGASTRIN AND THEIR USE | |
CY1122707T1 (en) | HETEROCYCLIC GLUTAMINASE INHIBITORS | |
CY1119591T1 (en) | SPECIAL CONNECTION PROTEINS AND THEIR USES | |
CY1124412T1 (en) | ANTI-DKK-1 ANTIBODIES | |
CY1117563T1 (en) | HER3 PARTS AND USE OF THESE | |
CY1119454T1 (en) | ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA | |
CY1121538T1 (en) | MONOCLONIC ANTIBODIES AGAINST TISSUE FACTOR INHIBITOR (TFPI) | |
CY1119410T1 (en) | OPTIMIZED monoclonal antibodies against the TFPI inhibitor (TFPI) | |
CY1118362T1 (en) | Piperidinone Cyanide CGRP Receptor Competitors | |
CY1118874T1 (en) | HUMANITIZED ANTIBODIES AGAINST LIV-1 AND USE FOR THERAPEUTIC TREATMENT | |
CY1119714T1 (en) | SUSPENSION UNIONS | |
ECSP088835A (en) | COMBINATORY THERAPY INVOLVING ALFA5BETA1 ANTAGONISTS | |
CY1116847T1 (en) | FGF-R4 Receptor Specific Antagonists | |
CY1118143T1 (en) | Heterocyclic compounds useful as PDK1 inhibitors | |
CY1118549T1 (en) | USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMISTRY FOR TREATMENT OF BREAST CANCER | |
EA201001639A1 (en) | COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND APPLICATION | |
CY1114272T1 (en) | Substituted dihydropyrosolones for the therapeutic treatment of cardiovascular and hematological diseases | |
BR112015009752A2 (en) | antibody / drug conjugates and methods of use | |
CY1120881T1 (en) | 5-HT3 RECEPTOR COMPETITORS | |
EA201200218A1 (en) | NEW BICYCLIC UREA COMPOUNDS | |
CY1112495T1 (en) | CYTAROTOXIC FACTORS INCLUDING NEW TOMAIMYKIN PRODUCERS |